Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Related Articles by Review for PubMed (Select 10403221)

1.

Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study.

McLean MJ, Morrell MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus-Miller L, Bernstein P, Rose-Legatt A.

Epilepsia. 1999 Jul;40(7):965-72.

PMID:
10403221
2.

Gabapentin.

Morris GL.

Epilepsia. 1999;40 Suppl 5:S63-70. Review.

PMID:
10530696
3.

Monotherapy trials with gabapentin for partial epilepsy.

Beydoun A.

Epilepsia. 1999;40 Suppl 6:S13-6; discussion S73-4. Review.

PMID:
10530677
4.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

5.

Clinical efficacy and safety of gabapentin.

Ramsay RE.

Neurology. 1994 Jun;44(6 Suppl 5):S23-30; discussion S31-2. Review.

PMID:
8022537
6.

Gabapentin.

McLean MJ.

Epilepsia. 1995;36 Suppl 2:S73-86. Review.

PMID:
8784216
7.

Gabapentin dosing in the treatment of epilepsy.

McLean MJ, Gidal BE.

Clin Ther. 2003 May;25(5):1382-406. Review.

PMID:
12867216
8.

[Current data on gabapentin].

Herranz JL.

Rev Neurol. 2000 Jun;30 Suppl 1:S125-31. Review. Spanish.

PMID:
10904979
9.
10.

Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.

Talati R, Scholle JM, Phung OP, Baker EL, Baker WL, Ashaye A, Kluger J, Coleman CI, White CM.

Pharmacotherapy. 2012 Apr;32(4):314-22. doi: 10.1002/j.1875-9114.2012.01099.x. Review.

PMID:
22461121
11.

[Gabapentin in children and adolescents with epilepsy].

Herranz JL.

Rev Neurol. 2002 Feb 16-28;34(4):384-7. Review. Spanish.

12.

[Characteristics and indications of gabapentin].

Sancho-Rieger J.

Rev Neurol. 2002 Sep;35 Suppl 1:S85-7. Review. Spanish.

13.

Options after the first antiepileptic drug has failed.

Elger CE, Fernández G.

Epilepsia. 1999;40 Suppl 6:S9-12; discussion S73-4. Review.

PMID:
10530676
14.

Gabapentin: pharmacokinetics, efficacy, and safety.

Beydoun A, Uthman BM, Sackellares JC.

Clin Neuropharmacol. 1995 Dec;18(6):469-81. Review.

PMID:
8681309
15.

[Monotherapy with gabapentin ++].

Padró L, Rovira R.

Rev Neurol. 1999 Sep 16-30;29(6):579-84. Review. Spanish.

PMID:
10584271
16.

Reporting and analysis of open-label extension studies of anti-epileptic drugs.

Maguire MJ, Hemming K, Hutton JL, Marson AG.

Epilepsy Res. 2008 Sep;81(1):24-9. doi: 10.1016/j.eplepsyres.2008.04.007. Epub 2008 Jun 2. Review.

PMID:
18514485
17.

[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].

Bittner S, Höhn K, Göbel K, Kleinschnitz C, Wiendl H, Meuth SG.

Nervenarzt. 2011 Oct;82(10):1273-80. doi: 10.1007/s00115-011-3321-8. Review. German.

PMID:
21647743
18.

[The safety and tolerability profile of gabapentin in optimal doses].

Cañadillas-Hidalgo FM.

Rev Neurol. 2004 Aug 16-31;39(4):371-80. Review. Spanish.

19.

Special considerations: use of lithium in children, adolescents, and elderly populations.

Tueth MJ, Murphy TK, Evans DL.

J Clin Psychiatry. 1998;59 Suppl 6:66-73. Review.

PMID:
9674939
20.

Adverse effects and safety profile of perampanel: a review of pooled data.

Rugg-Gunn F.

Epilepsia. 2014 Jan;55 Suppl 1:13-5. doi: 10.1111/epi.12504. Review.

PMID:
24400692
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk